GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Aims: The purpose of this study is to compare a combination of radiation therapy and weekly treatment of the chemotherapy drug cisplatin to the standard treatment for this type of cancer which is radiation therapy alone. This study will also evaluate the side effects of combining radiation therapy and chemotherapy with cisplatin. 
Diagnosis: Recurrent Endometrial Cancer 
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH09-122
Sponsor: Gynecologic Oncology Group (GOG) 
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes 

GOG 3005/AbbVie M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Aims: The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel and placebo followed by continued therapy with either veliparib or placebo to determine if it slows the progression of your cancer.  A BRCA gene test will be required for your participation to further assess treatment response.
Diagnosis: Previously untreated stage 3 or 4 ovarian, fallopian tube, or primary peritoneal cancer
Principal Investigator: Jean Hurteau, MD 
IRB Approval Number: EH15-265
Sponsor: AbbVie Inc
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GOG 0274: The OUTBACK Trial: A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Aims: The purpose of this study is to compare standard treatment; radiation therapy combined with the chemotherapy drug cisplatin (called chemo-radiation), to standard treatment plus additional investigational chemotherapy with the FDA approved agents, carboplatin and paclitaxel. The study will see if the addition of these chemotherapy agents will reduces the risk of tumor recurrence and improves overall survival. 
Diagnosis: Advanced Cervical Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH12-455
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact study nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measureable Stage II or IVA, Stage IVB, or Recurrent Endometrial Cancer
Aims: The purpose of this study is to find out if the drug combination paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating your type of cancer and to find out what side effects are caused by treatment with these drugs.
Diagnosis: Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH14-321
Sponsor: Gynecologic Oncology Group (GOG)
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: suspended

UC13-1235: A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy
Aims: The purpose of this study is to see if participants who receive 6 cycles of carboplatin plus either paclitaxel or docetaxel (standard chemotherapy ) plus metformin followed by metformin alone continued after the chemotherapy will have an improved outcome compared to those receiving 6 cycles of carboplatin plus either paclitaxel or docetaxel (standard chemotherapy) plus placebo followed by placebo alone continued after chemotherapy.  
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen) for which you have already undergone surgery
Principal Investigator: Gustavo Rodriguez, MD
IRB Approval Number: EH14-274
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Aims: The purpose of this study is to see if the combination of cediranib and olaparib, or each drug on it's own is as good or better than standard chemotherapy.  
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen) for which you have already had prior treatment
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH16-273
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Tara Flangan at 847.570.1768 or e-mail tflanagan@northshore.org
Open to Enrollment: Yes

Pilot Study of the Impact of Early Palliative Care on Quality of Life in Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Aims: The purpose of this study is to see if participants who see Palliative Care physicians at an earlier timepoint have a better quality of life.  
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen) for which you have already had treatment
Principal Investigator: Elena Diaz Moore, MD
IRB Approval Number: EH15-193
Sponsor: NorthShore
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

GOG 0281: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer
Aims: The purpose of this study is to see if participants who receive 6 cycles of carboplatin plus either paclitaxel or docetaxel (standard chemotherapy) plus metformin followed by metformin alone continued after the chemotherapy will have an improved outcome compared to those receiving 6 cycles of carboplatin plus either paclitaxel or docetaxel (standard chemotherapy) plus placebo followed by placebo alone continued after chemotherapy.   Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen) for which you have already undergone surgery Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH15-352
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

GOG 0264:A Randomized Phase III Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex-Cord Stomal Tumors of the Ovary
Aims: The purpose of the study is to compare the treatment with drugs, paclitaxel and carboplatin work better than treatment with the drugs bleomycin, etoposide and cisplatin, which is the standard of care treatment for this type of cancer.
Diagnosis: Sex-Cord Stromal tumors
Principal Investigator: Jean Hurteau, MD
IRB Approval Number: EH15-157
Sponsor: NRG-GOG
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768 or tflanagan@northshore.org
Open to Enrollment: Yes